An Abbreviated New Drug Application (ANDA) for three-times-a-week generic Copaxone (glatiramer acetate injection) filed by Mylan Inc has been accepted by the US Food and Drug Administration (US FDA).
According to a released issued by Natco Pharma Ltd here on Saturday, its marketing partner Mylan was one of the first companies to have filed a substantially complete ANDA containing a Paragraph IV certification for the product.
``It expects to be eligible for 180 days of marketing exclusivity in the U.S. upon final FDA approval,’’ the Hyderabad-based company said.
Copaxone is indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS).
In North America, it is marketed by Teva Neuroscience, Inc., which is a subsidiary of Teva and had sales of approximately $411.5 million for the 12 months ending June 30, 2014, according to IMS Health
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.